Stoke Therapeutics (STOK) Profit After Tax (2018 - 2026)
Stoke Therapeutics' (STOK) quarterly Profit After Tax came in at -$50.0 million in Q1 2026, down 144.28% year-on-year from $112.9 million in Q1 2025, and up 14.57% quarter-over-quarter from -$58.5 million in Q4 2025.
Stoke Therapeutics (STOK) Profit After Tax (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$50.0 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 144.28% year-over-year to -$50.0 million in Q1 2026; TTM through Mar 2026 was -$170.0 million, a 437.87% decrease from a year earlier, with the FY2025 full-year figure at -$6.9 million, up 92.26% from the prior year.
- Profit After Tax rose to -$50.0 million in Q1 2026 per STOK's latest filing, from -$58.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at $112.9 million in Q1 2025 and bottomed at -$58.5 million in Q4 2025.
- The 5-year median for Profit After Tax is -$25.7 million (2024), against an average of -$20.7 million.
- Biggest YoY gain for Profit After Tax was 528.17% in 2025; the steepest drop was 458.4% in 2025.
- Year by year, Profit After Tax stood at -$25.7 million in 2022, then retreated by 4.6% to -$26.8 million in 2023, then soared by 60.94% to -$10.5 million in 2024, then slumped by 458.4% to -$58.5 million in 2025, then gained by 14.57% to -$50.0 million in 2026.
- Per Business Quant, the three latest STOK Profit After Tax figures stand at -$50.0 million (Q1 2026), -$58.5 million (Q4 2025), and -$38.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -50.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.00 Mn |
| Dec 31, 2025 | -58.53 Mn |
| Sep 30, 2025 | -38.00 Mn |
| Jun 30, 2025 | -23.48 Mn |
| Mar 31, 2025 | 112.93 Mn |
| Dec 31, 2024 | -10.48 Mn |
| Sep 30, 2024 | -26.43 Mn |
| Jun 30, 2024 | -25.70 Mn |
| Mar 31, 2024 | -26.37 Mn |
| Dec 31, 2023 | -26.84 Mn |
| Sep 30, 2023 | -24.31 Mn |
| Jun 30, 2023 | -30.65 Mn |
| Mar 31, 2023 | -22.55 Mn |
| Dec 31, 2022 | -25.66 Mn |
| Sep 30, 2022 | -26.11 Mn |
| Jun 30, 2022 | -24.65 Mn |
| Mar 31, 2022 | -24.65 Mn |
| Dec 31, 2021 | -24.45 Mn |
| Sep 30, 2021 | -22.60 Mn |
| Jun 30, 2021 | -21.97 Mn |